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ABSTRACT
The SNP500Cancer database provides sequence and
genotype assay information for candidate SNPs use-
fulinmappingcomplexdiseases,suchascancer.The
database is an integral component of the NCI Cancer
Genome Anatomy Project (http://cgap.nci.nih.gov).
SNP500Cancerreportssequenceanalysisofanonym-
ized control DNA samples (n = 102 Coriell samples
representing four self-described ethnic groups:
African/African-American, Caucasian, Hispanic and
PacificRim).Thewebsiteissearchablebygene,chro-
mosome, gene ontology pathway, dbSNP ID and
SNP500Cancer SNP ID. As of October 2005, the data-
basecontains.13400SNPs,9124ofwhichhavebeen
sequenced in the SNP500Cancer population. For
each analysed SNP, gene location and .200 bp of
surrounding annotated sequence (including nearby
SNPs) are provided, with frequency information in
total and per subpopulation as well as calculation
of Hardy–Weinberg equilibrium for each subpopula-
tion. The website provides the conditions for valid-
ated sequencing and genotyping assays, as well as
genotyperesultsforthe102samples,inbothviewable
anddownloadableformats.Asubsetofsequenceval-
idated SNPs with minor allele frequency .5% are
entered into a high-throughput pipeline for genotyp-
ing analysis to determine concordance for the same
102 samples. In addition, the results of genotype
analysis for select validated SNP assays (defined as
100% concordance between sequence analysis and
genotype results) are posted for an additional 280
samples drawn from the Human Diversity Panel
(HDP). SNP500Cancer provides an invaluable
resourceforinvestigatorstoselectSNPsforanalysis,
design genotyping assays using validated sequence
data, choose selected assays already validated on
one or more genotyping platforms, and select
reference standards for genotyping assays. The
SNP500Cancer database is freely accessible via the
web page at http://snp500cancer.nci.nih.gov.
INTRODUCTION
SNP500Cancer is a component of the Cancer Genome Ana-
tomy Project (CGAP) of the National Cancer Institute (NCI)
and is speciﬁcally designed to generate resources for the iden-
tiﬁcation and characterization of genetic variation in genes
important in cancer (1). The database reports the validation
of SNPs by sequence analysis and optimizes genotyping
assays for SNPs of interest to molecular epidemiology studies
in cancer.
CGAP is dedicated to the development of technology,
including both assays and utilization of technical platforms,
and to determining the gene expression proﬁles of normal,
precancer and cancer cells (2). Accordingly, data pertaining
to genes and their variation are available on the public website
http://cgap.nci.nih.gov. SNP500Cancer represents one of sev-
eral initiatives designed to characterize sequence variation and
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in the etiology of different cancers as well as related pheno-
types. A validated SNP in the database has 100% concordance
between sequence analysis and genotyping results on one or
more platforms. Assays are developed and optimized in the
Core Genotyping Facility (CGF) of the NCI for associations
studies conducted in the Division of Cancer Epidemiology and
Genetics (DCEG) and the Center for Cancer Research within
the Intramural Program of the NCI. The primary focus of the
DCEG’s intramural studies is to conduct population-based
research on environmental and genetic determinants of cancer.
DNA SAMPLES
Sequence and genotype analysis are conducted in a set of 102
unique anonymized individuals of diverse geographic origin
with self-described ethnic group afﬁliation information, cho-
sen to represent four major ethnic groups in the USA; it
includes 24 African/African-American, 31 Caucasian, 23 His-
panic and 24 Paciﬁc Rim individuals. The 102 anonymized
samples can be obtained from the Coriell Cell Repositories
(Coriell Institute for Medical Research, Camden, NJ). The sets
of individuals are not a random sampling of one or more
human populations and thus the predictive value of the
sequence and genotype data provided can vary for different
population samples.
A subset of SNPs has been genotyped in 280 anonymized
individuals drawn from the Human Diversity Panel (HDP) (3),
using DNA that has been ampliﬁed by whole genome ampli-
ﬁcation (4). The ethnic distribution of the 280 individuals
approximates the 102 of the SNP500Cancer set, namely,
the four self-described ethnic groups listed here. It is notable
that there are 49 Native Americans, 25 of Mayan background
and 24 of Piman background.
SELECTION OF GENES AND SNPS
This database is biased towards SNPs that lie within or are
situated close to ‘candidate’ genes. The selection of genes and
SNPs for analysis has been drawn from the following sources:
(i) genes that ﬁt a plausible model for cancer studies (e.g. by
pathway), (ii) review of the published literature on SNPs and
cancer, (iii) SNPs reported in public databases with some
associated non-in silico determined frequency and (iv) SNPs
veriﬁed during re-sequence analysis of candidate genes (5). In
addition, the database contains SNPs analysed in the Breast
and Prostate Cohort Consortium (http://epi.grants.cancer.gov/
BPC3/ and http://cgf.nci.nih.gov/cohort.cfm), which targets
the genes of the sex steroid metabolism and insulin growth
factor pathways (n ¼ 55 in total).
As of October 2005, the database contains SNPs in 812
known genes. The average number of SNPs per gene is 14.1
and the median is 8 SNPs per gene; the range is between 1 and
237 SNPs per gene.
SEQUENCING PROTOCOL
A PCR amplicon of  600 bp is generated for each SNP,
which is localized to the center, creating ﬂanking regions
of  300 bp in each direction. Additional putative SNPs
(determined from dbSNP) are annotated on the sequence of
the amplicon. Oligonucleotide primers are designed for
bi-directional sequence analysis using Primer3 software (6)
and ProbeITy primer design software (Celadon Laboratories,
Hyattsville MD). Each oligonucleotide primer is extended
with a universal sequencing primer, M13 forward (TGTA-
AAACGACGGCCAGT) or M13 reverse (CAGGAAA-
CAGCTATGACC). The sequencing assay protocols and
conditions are displayed on the SNP500Cancer website.
Sequence tracings are analysed in Seqscape v2.5 (Applied
Biosystems, Foster City, CA). A sequencing call is deemed
acceptable if the Seqscape quality score is >20 for at least
98 of the 102 individuals. Genotype calls are determined for
each of the 102 individuals. The genotype and allele frequen-
cies are maintained in an Oracle database and displayed on
the SNP500Cancer website.
GENOTYPING PROTOCOLS AND VALIDATION
For SNPs that are determined to have >5% minor allele fre-
quency (MAF) in at least one of the SNP500Cancer subpopu-
lations,  200 bp of DNA sequence surrounding each SNP
is submitted for design on one of the CGF’s genotyping plat-
forms: (i) Applied Biosystems’ TaqMan  ‘Assay by Design’
service and (ii) EPOCH Biosciences’ MGB Eclipse 
probes. The genotyping assay procedures and conditions are
displayed on the SNP500Cancer website. Genotyping assays
are validated if there is complete concordance between
the genotype results and the primary sequence analysis for
the 102 samples. In addition, the 280 HDP samples are geno-
typed for SNPs with >5% MAF. The frequencies found in
the four HDP subpopulations are displayed on the
SNP500Cancer website.
ANALYSIS OF ALLELE FREQUENCIES
For each validated SNP, allele and genotype frequencies
are displayed for the 102 individuals overall (Figure 1) and
for each SNP500Cancer subpopulation. The result of a test for
Hardy–Weinberg equilibrium, c
2 with one degree of freedom
for two alleles (7) is posted for each subpopulation.
Theobserved allele frequencies inthe SNP500Cancerpopu-
lation ofn ¼ 102 can provide a useful estimate overall, as well
asforthefoursubgroups.Inananalysisof1164SNPsgenotyped
intheadditional280individualscomparedwiththedataforthe
102 which were both genotyped and sequenced, the coefﬁcient
of correlation (r
2) for each group was as follows: Caucasian
0.948, African-American 0.922, Paciﬁc Rim 0.919 and His-
panic 0.742. The latter is notable because of the differences
in the degree of admixture between the Hispanic subgroup of
the102andthetwoNativeAmericanpopulations,ofMayaand
Pima heritage. Analysis of the SNP500Cancer dataset can be
useful in estimating gene diversity. For instance, consistently
reduced genetic diversityhas been observed for SNP loci caus-
ing amino acid changes, especially radical shifts in protein
structure (8); a similar trend was observed for 50-untranslated
regions(50-UTRs).Moreover,thereductionofgeneticdiversity
ofnonsynonymousSNPsandthosewithinthe50-UTRareevid-
ence that purifying selection could have acted at these sites,
leading to reduced interpopulation divergence (9).
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All analysed SNPs from the SNP500Cancer project are sub-
mitted to dbSNP (10)—http://www.ncbi.nlm.nih.gov/SNP.
This information includes ﬂanking sequence, observed vari-
ation, assay primers, probes, and conditions, and frequency of
the sequence variation among the SNP500Cancer total popu-
lation and subpopulations. Figure 2 depicts the distribution of
SNPs already in dbSNP and those newly observed in close
proximity to target SNPs. It is also notable that  10% of
targeted SNPs are monoallelic in the 102 samples when com-
pared with data in dbSNP build 124.
DATABASE AND WEB SERVER SPECIFICATIONS
The SNP500Cancer database is implemented using Oracle 9i
(Oracle Corporation, Redwood Shores, CA). The web inter-
face is written in ColdFusion (Macromedia, San Francisco,
CA). The web server is a Compaq (Cupertino, CA) DL585
running Linux version 2.6.5. The database server is a Sun
Microsystems (Santa Clara, CA) Sunﬁre 4800 running Oracle
version 9.2.0.6.0. Both servers are supported by NCI
Computer Services (Rockville, MD).
SNP500Cancer data are available through the caGRID,
part of the Cancer Biomedical Informatics Grid (caBIG),
a common interface providing data sharing among cancer
researchers worldwide (http://cabig.nci.nih.gov) (11).
USING THE SNP500CANCER WEBSITE
Searching for genes
The SNP500Cancer website provides capabilities for search-
ing for genes in several ways: (i) gene name or alias (including
wild card searches), (ii) chromosome location and (iii) Gene
Ontology (GO) pathway (12)—numeric or text. The gene is
displayed with a list of SNPs that have been validated, and
those that were not found to occur in the SNP500Cancer
population.
Searching for SNPs
SNPs can be searched for using the dbSNP ID (rs cluster
number, e.g. rs799917), or the internal SNP500Cancer poly-
morphism ID (gene symbol followed by a sequence number,
e.g. BRCA1-02). The SNP is displayed in the center of
surrounding sequence, and other SNPs in the sequence are
annotated with IUPAC codes (Figure 1). Clicking on the
SNP variation links to Genewindow (13), a publicly available
genome browser developed at the CGF.
Viewing genotypic and allelic frequencies
For the SNP of interest, genotypic and allelic frequencies for
the entire SNP500Cancer population of 102 individuals are
displayed. The ‘view subpopulation frequencies’ link displays
Figure 1. The SNP page for a typical SNP from the SNP500Cancer website,
showing links to external resources, the SNP within flanking sequence,
frequency data and links to assay information.
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Figure 2. Thedistributionof13.437SNPsinSNP500Cancer—thosealreadyin
dbSNP, those not yet in dbSNP (submitted for next build). Almost 10% of
SNP500Cancer SNPs were found to have no variation in the set of 102
individuals of the SNP500Cancer population overall, even though they are
in dbSNP.
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subpopulation—African/African-American, Caucasian, His-
panic and Paciﬁc Rim. Each subpopulation link leads to a
list of individual genotypes for the samples within that
subpopulation.
Viewing haplotype and htSNP data
For the gene of interest, haplotypes and haplotype-tagging
SNPs (htSNP) data can be displayed for the entire control
population or by subpopulation. Two different programs are
available for determination of htSNPs: TagSNPs (14) and
Tagger (http://www.broad.mit.edu/mpg/tagger/). The haplo-
type block structure can be visualized using Haploview (15).
Displaying assay conditions
For the SNP of interest, links are displayed for all validated
assays (sequencing, MGB Eclipse , TaqMan ). The link
displays a page with detailed information on primers, probes,
temperature and procedural steps.
Downloading information via FTP
FTP ﬁles are posted for SNPs by gene (including identiﬁers,
genomic location and amino acid change), assays (identiﬁer,
primers, probesandconditions),frequencies andgenotypesfor
each SNP with variation, as well as genotypes for all SNPs
with >5% allelic frequency. These ﬁles can be found at ftp://
ftp-snp500cancer.nci.nih.gov.
Connecting to other information sources
Each gene and SNP page on the SNP500Cancer website
includes links to external resources; for genes: Entrez (16)
and GO database; for SNPs: dbSNP, NCBI MapViewer (17)
and Ensembl (18).
FUTURE DIRECTIONS
SNP500Cancer is a genetic resource designed to provide data
on SNPs with neighboring sequence, for design and optimiza-
tion of genotyping assays to be used in molecular epidemi-
ology studies of cancer. A major goal of SNP500Cancer is to
increase the breadth of genes and speciﬁcally develop sets of
genes within a common pathway (e.g. DNA repair or telomere
stability) (19). To this end, the project will utilize public
resources to identify and validate SNPs across each gene at
a greater density (e.g. one SNP every 1–3 kb) (20). The addi-
tional SNPs needed to densely cover the genes of interest will
be selected based on their location, as well as suitability for
inclusion as an htSNP in one or more population. The project
will also add SNPs ofgreatimportance to cancer based on high
quality citations in the published literature (21). There will be
a special emphasis on SNPs drawn from coding and regulatory
regions (including microRNAs) as well as those SNPs that
have been shown to be associated with cancer susceptibility
or outcome, particularly in pharmacogenomics.
SNPs with validated sequencing performed in other public
projects will be imported, and assays optimized based on the
concordance between sequence and genotype analysis. For
instance, current plans are underway to optimize and validate
assays for SNPs identiﬁed in the NIEHS Environmental
Genome Project (NIEHS SNPs. NIEHS Environmental
Genome Project, University of Washington, Seattle, WA,
http://egp.gs.washington.edu/).
Though the primarygoal of the SNP500Cancer database has
been to focus on SNPs in and around known genes, future
plans include the results of sequence analysis around small
RNA sequences and their possible targets in cancer. Lastly,
SNP500Cancer will make available results of dense, whole
genome SNP scans using the 102 samples.
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